Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2313 - 2320 of 12143 results

Boston Legal Teams Brace For Wave Of Uncharted Battles Over Abortion
September 2, 2022| News

What's New in 5G - September 2022
September 1, 2022| Blog| Viewpoint

Telehealth Update: Assessing PHE Flexibilities, Pending Legislation Entering Fall 2022
September 1, 2022| Blog| Viewpoint

Some Institutional LPs Have Started Pulling Back From VC, But Most Won’t
September 1, 2022| News

Fourth Circuit Holds Gender Dysphoria is a Protected Disability Under the ADA
August 31, 2022| Blog| Viewpoint

New York Office of Medicaid Inspector General Proposes Regulations on Medicaid Managed Care Fraud, Waste, and Abuse Prevention
August 31, 2022| Blog| Viewpoint

Will ‘Dobbs’ Advice Erode the Attorney-Client Privilege?
August 31, 2022| News

State Climate Bill Puts Massachusetts at ‘Forefront of Clean Energy Legislation’
August 31, 2022| News
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
